Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
Morgan Stanley Smith Barney LLC submitted a notice regarding the proposed sale of 1,000 common shares via stock option exercise, with the transaction dated 02/25/2026 and cash proceeds indicated. The filing also lists two prior sales by Christopher Causey: $510,000.00 on 01/06/2026 for 1,000 shares and $500,014.60 on 01/02/2026 for 1,000 shares.
UNITED THERAPEUTICS Corp director Christopher Causey reported option exercises and a share sale. He exercised stock options for 1,000 shares on February 25, 2026, converting derivative securities at a stated price of $0.0000 and acquiring 1,000 shares of common stock at $119.7600 per share.
On the same date, he sold 1,000 shares of common stock at $520.0000 per share in an open-market transaction. After these transactions, he directly held 4,190 shares of common stock and 6,320 stock options. The exercise and subsequent sale were made under a Rule 10b5-1 trading plan entered into on September 30, 2025.
United Therapeutics Corporation reported strong fourth quarter and full year 2025 results, highlighted by record annual revenues of $3.18 billion, up 11% from 2024, and net income of $1.33 billion versus $1.20 billion a year earlier.
Growth was driven mainly by Tyvaso DPI, with 2025 sales of $1.29 billion, up 25%, and total Tyvaso revenues rising 16% to $1.88 billion, helped by higher patient numbers and Medicare Part D redesign effects. Orenitram sales increased 14% to $496.9 million. The company invested $550.0 million in research and development and recorded a $21.7 million PP&E impairment. It also executed accelerated share repurchase agreements totaling $2.0 billion, receiving 2.64 million shares in 2025, while ending the year with $4.70 billion in cash, cash equivalents, and marketable investments and stockholders’ equity of $7.10 billion. Management highlighted upcoming ADVANCE OUTCOMES and TETON-1 clinical readouts and expressed confidence in sustaining double-digit revenue growth.
United Therapeutics is a public benefit corporation focused on treating pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and other serious diseases while developing manufactured organs and organ alternatives.
The company’s core drugs are treprostinil-based therapies Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram, plus oncology drug Unituxin and PDE‑5 inhibitor Adcirca. In 2025, combined Tyvaso DPI and Nebulized Tyvaso net product sales were $1,878.2 million, about 59% of total revenue, with Remodulin at $526.8 million, Orenitram at $496.9 million, Unituxin at $226.8 million, and Adcirca at $30.0 million.
Pipeline highlights include positive phase 3 TETON 2 data for Nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) and the global phase 3 ADVANCE OUTCOMES study of oral prostacyclin agonist ralinepag in PAH. Beyond drugs, the company is advancing xenotransplantation (UKidney and UThymoKidney clinical studies), regenerative programs such as miroliverELAP, and ex vivo lung perfusion services, while investing in low‑emission air transport for organ delivery.
UNITED THERAPEUTICS Corp president and COO Michael Benkowitz reported option exercises and related sales of common stock through trusts on February 23, 2026. Trusts associated with him exercised options for 9,375 and 5,065 shares, then sold those same amounts in open-market transactions at $472.126 per share.
The activity was carried out under a Rule 10b5-1 trading plan that was previously established and these are the final transactions under that plan. Following these indirect trust transactions, Benkowitz directly holds 2,648 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. He exercised options for 8,300 shares of common stock at a price of $146.03 per share and received the underlying shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices ranging from about $471 to $479 per share under a pre-arranged Rule 10b5-1 plan entered on August 11, 2025. After these transactions, he directly owned 36,781 shares of UNITED THERAPEUTICS common stock.
Paul Mahon submitted a Form 144 proposing to sell 8,300 common shares via a stock options exercise with an intended transaction date of 02/19/2026. The filing also lists multiple recent dispositions by the same person, including sales of 8,300 shares on 02/05/2026 and 8,300 shares on 01/15/2026.
UNITED THERAPEUTICS Corp president and COO Michael Benkowitz reported option exercises and related sales of common stock held in family trusts. On February 17, 2026, trusts associated with him exercised options for 14,625 and 7,875 shares, then sold the resulting 22,500 shares in open-market transactions at $480.7536 per share under a pre-established Rule 10b5-1 trading plan entered into on June 3, 2025. After these indirect transactions, Benkowitz continued to hold 2,648 shares of common stock directly.
United Therapeutics director Malcolm Jan reported an open-market sale of company stock. On February 17, 2026, he sold 50 shares of United Therapeutics common stock at a price of $474.68 per share in a transaction coded as an open-market sale.
After this transaction, Jan directly holds 220 shares of United Therapeutics common stock. The sale was carried out under a pre-established Rule 10b5-1 trading plan that he entered into on September 11, 2025, which automates trades according to preset instructions.
An affiliate of UTHR has filed a notice under Rule 144 to sell 50 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 17, 2026 and an aggregate market value of 23734.00.
The 50 shares were acquired as restricted stock from the issuer on June 26, 2025, with payment recorded the same day. Over the past three months, the same seller has completed several additional 50‑share sales of UTHR common stock, each generating disclosed gross proceeds.